December 18, 2025 06:03 am (IST)
Follow us:
Strides Arcolab signs agreement with Gilead Sciences
Bangalore/Kolkata, Jan 20 (IBNS): Strides Arcolab Limited (Strides) on Tuesday announced that it has entered into a licensing agreement with Gilead Sciences, Inc. under which Gilead has extended non-exclusive rights to Strides to manufacture and distribute Tenofovir Alafenamide (TAF), both as a single agent product and in combination with other drugs.
The license being granted to Strides extends to 112 countries, which together account for more than 30 million people living with HIV.
As part of the licensing agreement, pending U.S. Food and Drug Administration (US FDA) approval of the Gilead product, Strides will receive a technology transfer from Gilead, enabling Strides to manufacture low-cost versions of TAF for developing countries.
TAF is a novel nucleotide reverse transcriptase inhibitor that has demonstrated high antiviral efficacy at a dose 10 times lower than Gilead’s Viread (tenofovir disoproxil fumarate), as well as an improved renal and bone safety profile.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
SBI rolls out YONO 2.0! Banking gets a major digital upgrade
Wed, Dec 17 2025
Nephrocare IPO pops on debut, dialysis major lists at 7% premium
Wed, Dec 17 2025
Rupee hits new lifetime low, but top economist says ‘don’t panic’
Wed, Dec 17 2025
How AI will reshape India: TCS and CII drop their report
Tue, Dec 16 2025
Why Gold Loans Are a Better Option than Selling Your Gold?
Tue, Dec 16 2025